Caris Life Sciences has incorporated a new capecitabine breast‑cancer signature into its Caris AI Insights section of the Caris Molecular Tumor Board Report. The signature analyzes more than 2,000 expression and copy‑number features derived from a patient’s whole‑exome and whole‑transcriptome data to predict response to capecitabine in first‑line therapy for HER2‑negative breast cancer patients.
The addition builds on Caris’s strategy of leveraging its extensive clinico‑genomic database—over 660,000 matched patient records—to develop AI‑driven biomarkers. The new signature is part of the MI Cancer Seek platform, which received FDA approval in November 2024 as the first whole‑exome and whole‑transcriptome assay with companion diagnostic indications for solid‑tumor profiling. By integrating the capecitabine signature into the existing report, Caris enhances the clinical utility of its profiling platform and reinforces its position as a leader in AI‑enabled precision oncology.
Capecitabine is an oral chemotherapy agent used in HER2‑negative breast cancer, but its effectiveness can vary. The predictive signature enables clinicians to identify patients most likely to benefit from the drug, potentially improving treatment selection and outcomes. This capability aligns with Caris’s broader goal of providing actionable insights that translate large genomic datasets into tangible therapeutic decisions.
"Molecular profiling is a vital step in gaining a comprehensive understanding of a patient’s cancer. Caris AI Insights help researchers and clinicians provide a valuable molecular blueprint of a patient’s tumor biology and is another way Caris’ testing goes above and beyond for patients, clinicians and researchers," said David Spetzler, President of Caris. The quote underscores the company’s commitment to AI‑driven innovation and its potential to drive increased test volume and pricing power in the oncology diagnostics market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.